datamatters24/research-document-archive huggingface dataset:
‘‘(D) REVIEW.—Not less than annually, 
the corporation shall review the progress of 
each community development organization re-
ceiving assistance under this section in carrying 
out its strategic plan, meeting its performance 
goals, and satisfying the terms and conditions 
of its assistance agreement. 
‘‘(E) ANNUAL REPORTS.— 
‘‘(i) REQUIREMENT.—The corporation 
shall require each community development 
organization receiving assistance under 
this section to submit to the corporation, 
in such form and manner as the corpora-
tion shall require, an annual report regard-
ing its activities, its financial condition, 
and its success in meeting performance 
goals, in satisfying the terms and condi-
tions of its assistance agreement, and in 
complying with other requirements of this 
section. 
‘‘(ii) AVAILABILITY.—After deleting 
or redacting any material as appropriate to 
protect privacy or proprietary interests, the 
corporation shall make such reports avail-
able for public inspection. 
VerDate Aug 31 2005 
21:50 Feb 26, 2008
Jkt 069200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H5487.IH
H5487
hsrobinson on PROD1PC76 with BILLS
110TH CONGRESS 
2D SESSION 
H. R. 5489 
AN ACT 
To designate the facility of the United States Postal Service 
located at 6892 Main Street in Gloucester, Virginia, as 
the ‘‘Congresswoman Jo Ann S. Davis Post Office’’. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
sion Act (15 U.S.C. 41 et seq.) were incorporated 
into and made a part of this Act. Nothing contained 
in this Act shall be construed to limit the authority 
of the Commission under any other provision of law. 
(2) ACTIONS BY STATES.— 
(A) CIVIL ACTIONS.—In any case in which 
the attorney general of a State has reason to 
believe that an interest of the residents of that 
State has been or is threatened or adversely af-
fected by an act or practice that violates any 
regulation of the Commission promulgated 
under subsection (b), the State, as parens 
patriae, may bring a civil action on behalf of 
the residents of the State in a district court of 
the United States of appropriate jurisdiction, 
to— 
(i) enjoin that act or practice; 
(ii) enforce compliance with the regu-
lation; 
(iii) obtain damages, restitution, or 
other compensation on behalf of residents 
of the State; or 
(iv) obtain such other legal and equi-
table relief as the district court may con-
sider to be appropriate.
‘‘(M) expenditures for which a deduction is 
allowed under section 179F.’’. 
(3) Section 312(k)(3)(B) of such Code is 
amended by striking ‘‘or 179E’’ each place it ap-
pears in the heading and text and inserting ‘‘179E, 
or 179F’’. 
(4) The table of sections for part VI of sub-
chapter B of chapter 1 of such Code is amended by 
inserting after the item relating to section 179E the 
following new item: 
‘‘Sec. 179F. Election to expense certain property used in refining ethanol, 
methanol, and biodiesel.’’. 
(c) EFFECTIVE DATE.—The amendments made by 
this section shall apply to property placed in service after 
the date of the enactment of this Act. 
Æ 
VerDate Nov 24 2008 
21:28 Mar 31, 2009
Jkt 079200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6301
E:\BILLS\H1794.IH
H1794
pwalker on PROD1PC71 with BILLS
109TH CONGRESS 
1ST SESSION 
H. CON. RES. 178
CONCURRENT RESOLUTION 
Recognizing the need to pursue research into the 
causes, a treatment, and an eventual cure for idi-
opathic pulmonary fibrosis, supporting the goals 
and ideals of National Idiopathic Pulmonary Fi-
brosis Awareness Week, and for other purposes.
109TH CONGRESS 
1ST SESSION 
H. CON. RES. 178
CONCURRENT RESOLUTION
Whereas idiopathic pulmonary fibrosis is a serious lung dis-
order causing progressive, incurable lung scarring; 
Whereas idiopathic pulmonary fibrosis is one of about 200 
disorders called interstitial lung diseases; 
Whereas idiopathic pulmonary fibrosis is the most common 
form of interstitial lung disease;
•HCON 178 EH 
Whereas idiopathic pulmonary fibrosis is a debilitating and 
generally fatal disease marked by progressive scarring of 
the lungs, causing an irreversible loss of the lung tissue’s 
ability to transport oxygen; 
Whereas idiopathic pulmonary fibrosis progresses quickly, 
often causing disability or death within a few short years; 
Whereas there is no proven cause of idiopathic pulmonary fi-
brosis; 
Whereas approximately 83,000 United States citizens have 
idiopathic pulmonary fibrosis, and 31,000 new cases are 
diagnosed each year; 
Whereas idiopathic pulmonary fibrosis is often misdiagnosed 
or underdiagnosed; 
Whereas the median survival rate for idiopathic pulmonary fi-
brosis patients is 2 to 3 years, and about two thirds of 
idiopathic pulmonary fibrosis patients die within 5 years; 
and 
Whereas a need has been identified to increase awareness and 
detection of this misdiagnosed and underdiagnosed dis-
order: Now, therefore, be it
Resolved by the House of Representatives (the Senate 
concurring), That the Congress—
(1) recognizes the need to pursue research into 
the causes, a treatment, and an eventual cure for id-
iopathic pulmonary fibrosis; 
(2) supports the work of advocates and organi-
zations in educating, supporting, and providing hope 
for individuals who suffer from idiopathic pulmonary
•HCON 178 EH 
fibrosis, including efforts to organize a National Idi-
opathic Pulmonary Fibrosis Awareness Week; 
(3) supports the designation of an appropriate 
week as National Idiopathic Pulmonary Fibrosis 
Awareness Week; 
(4) encourages the President to issue a procla-
mation designating a National Idiopathic Pulmonary 
Fibrosis Awareness Week; 
(5) congratulates advocates and organizations 
for their efforts to educate the public about idio-
pathic pulmonary fibrosis, while funding research to 
help find a cure for this disorder; and 
(6) supports the goals and ideals of National 
Idiopathic Pulmonary Fibrosis Awareness Week.
Passed the House of Representatives September 29, 
2005. 
Attest:
Clerk.
Before filing an action under this subsection, 
the attorney general of the State involved shall 
provide to the Commission and to the Attorney 
General a written notice of that action and a 
copy of the complaint for that action. If the 
State attorney general determines that it is not 
feasible to provide the notice described in this 
subparagraph before the filing of the action, the 
State attorney general shall provide the written 
notice and the copy of the complaint to the 
Commission and to the Attorney General as 
soon after the filing of the complaint as prac-
ticable. 
(B) COMMISSION AND ATTORNEY GENERAL 
AUTHORITY.—On receiving notice under sub-
paragraph (A), the Commission and the Attor-
ney General each shall have the right— 
(i) to move to stay the action, pending 
the final disposition of a pending Federal 
matter as described in subparagraph (C); 
(ii) to intervene in an action under 
clause (i); 
(iii) upon so intervening, to be heard 
on all matters arising therein; and 
(iv) to file petitions for appeal.
(C) PENDING CRIMINAL PROCEEDINGS.—If 
the Attorney General has instituted a criminal 
proceeding or the Commission has instituted a 
civil action for a violation of this Act or any 
regulations thereunder, no State may, during 
the pendency of such proceeding or action, 
bring an action under this section against any 
defendant named in the criminal proceeding or 
civil action for any violation of this section that 
is alleged in that proceeding or action. 
(D) RULE OF CONSTRUCTION.—For pur-
poses of bringing any civil action under sub-
paragraph (A), nothing in this Act shall be con-
strued to prevent an attorney general of a State 
from exercising the powers conferred on the at-
torney general by the laws of that State to con-
duct investigations, administer oaths and affir-
mations, or compel the attendance of witnesses 
or the production of documentary and other evi-
dence. 
(E) VENUE; SERVICE OF PROCESS.—Any 
action brought under this section may be 
brought in any district court of the United 
States that meets applicable requirements relat-
ing to venue under section 1391 of title 28,
United States Code. In an action brought under 
this section, process may be served in any dis-
trict in which the defendant is an inhabitant or 
may be found. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 1079 
To provide that the approved application under the Federal Food, Drug, 
and Cosmetic Act for the drug commonly known as RU–486 is deemed 
to have been withdrawn, to provide for the review by the Comptroller 
General of the United States of the process by which the Food and 
Drug Administration approved such drug, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 3, 2005 
Mr. BARTLETT of Maryland (for himself, Mr. HALL, Mr. WICKER, Mr. MIL-
LER of Florida, Mr. NORWOOD, Mr. SMITH of New Jersey, Mr. WAMP, 
Mr. PITTS, Mr. CHABOT, Mrs. BLACKBURN, Mr. BAKER, Mr. FORBES, 
Mr. WELDON of Florida, Mr. ROGERS of Alabama, Mr. SHIMKUS, Mrs. 
JO ANN DAVIS of Virginia, Mr. DAVIS of Kentucky, Mr. AKIN, Ms. 
HART, Mr. GINGREY, Mr. PICKERING, Mr. KING of Iowa, Mr. RYUN of 
Kansas, Mrs. MUSGRAVE, Mr. ADERHOLT, Mr. INGLIS of South Carolina, 
Mr. DAVIS of Tennessee, Mr. RENZI, Mr. JONES of North Carolina, Mr. 
STEARNS, Mr. CANTOR, Mr. MCCOTTER, Mrs. MYRICK, Mr. BEAUPREZ, 
Mr. FRANKS of Arizona, Mr. PENCE, Mr. SAM JOHNSON of Texas, Mr. 
TERRY, Mr. TIBERI, Mr. DOOLITTLE, Mr. ROGERS of Kentucky, Mr. 
SOUDER, Mr. BROWN of South Carolina, Mr. KENNEDY of Minnesota, 
Mr. BOOZMAN, Mr. WHITFIELD, Ms. FOXX, and Mrs. EMERSON) intro-
duced the following bill; which was referred to the Committee on Energy 
and Commerce 
A BILL 
To provide that the approved application under the Federal 
Food, Drug, and Cosmetic Act for the drug commonly 
known as RU–486 is deemed to have been withdrawn, 
to provide for the review by the Comptroller General 
of the United States of the process by which the Food
and Drug Administration approved such drug, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘RU–486 Suspension 
and Review Act of 2005’’. 
SEC. 2. FINDING. 
The Congress finds that the use of the drug 
mifepristone (marketed as Mifeprex, and commonly known 
as RU–486) in conjunction with the off-label use of 
misoprostol to chemically induce abortion has caused a 
significant number of deaths, near deaths, and adverse re-
actions. 
SEC. 3. SUSPENSION OF APPROVAL OF DRUG COMMONLY 
KNOWN AS RU–486; REVIEW AND REPORT BY 
GOVERNMENT ACCOUNTABILITY OFFICE. 
(a) IN GENERAL.—Effective upon the expiration of 
14 days after the date of the enactment of this Act: 
(1) The approved application under section 
505(b) of the Federal Food, Drug, and Cosmetic Act 
for the drug mifepristone (marketed as Mifeprex, 
and commonly known as RU–486) is deemed to have 
been withdrawn under section 505(e) of such Act. 
(2) For purposes of sections 301(d) and 304 of 
such Act, the introduction or delivery for introduc-
tion of such drug into interstate commerce shall be 
considered a violation of section 505 of such Act. 
(3) The drug misoprostol shall be considered 
misbranded for purposes of sections 301 and 304 of 
such Act if the drug bears labeling providing that 
the drug may be used for the medical termination of 
intrauterine pregnancy or that the drug may be used 
in conjunction with another drug for the medical ter-
mination of intrauterine pregnancy. 
(b) REVIEW AND REPORT BY GENERAL ACCOUNTING 
OFFICE.— 
(1) IN GENERAL.—The Comptroller General of 
the United States shall review the process by which 
the Food and Drug Administration approved 
mifepristone under section 505 of the Federal Food, 
Drug, and Cosmetic Act and shall determine wheth-
er such approval was provided in accordance with 
such section. The Secretary of Health and Human 
Services shall ensure that the Comptroller General 
has full access to all information possessed by the 
Department of Human Services that relates to such 
process. 
(2) REPORT.—Not later than 180 days after 
the date of the enactment of this Act, the Comp-
troller General shall complete the review under para-
(1) REVIEW.—The Comptroller General shall 
review the demonstration project on an ongoing 
basis. 
(2) REPORTS.—The Comptroller General shall 
submit to Congress a report on the Comptroller 
General’s findings and recommendations concerning 
the demonstration project—
(A) after the operation of the demonstra-
tion project for a period of one year; and 
(B) after the operation of the demonstra-
tion project for a period of two years. 
(j) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to the Secretary of Veterans 
Affairs for the conduct of the demonstration project under 
this section the sum of $10,000,000. 
SEC. 6. PARKINSON’S DISEASE RESEARCH, EDUCATION, 
AND CLINICAL CENTERS. 
(a) REQUIREMENT FOR ESTABLISHMENT OF CEN-
TERS.—
(1) IN GENERAL.—Subchapter II of chapter 73 
of title 38, United States Code, is amended by add-
ing at the end the following new section:
III 
109TH CONGRESS 
1ST SESSION 
H. CON. RES. 178 
IN THE SENATE OF THE UNITED STATES 
SEPTEMBER 30, 2005 
Received and referred to the Committee on Health, Education, Labor, and 
Pensions 
CONCURRENT RESOLUTION 
Recognizing the need to pursue research into the causes, 
a treatment, and an eventual cure for idiopathic pul-
monary fibrosis, supporting the goals and ideals of Na-
tional Idiopathic Pulmonary Fibrosis Awareness Week, 
and for other purposes. 
Whereas idiopathic pulmonary fibrosis is a serious lung dis-
order causing progressive, incurable lung scarring; 
Whereas idiopathic pulmonary fibrosis is one of about 200 
disorders called interstitial lung diseases; 
Whereas idiopathic pulmonary fibrosis is the most common 
form of interstitial lung disease;
HCON 178 RFS 
Whereas idiopathic pulmonary fibrosis is a debilitating and 
generally fatal disease marked by progressive scarring of 
the lungs, causing an irreversible loss of the lung tissue’s 
ability to transport oxygen; 
Whereas idiopathic pulmonary fibrosis progresses quickly, 
often causing disability or death within a few short years; 
Whereas there is no proven cause of idiopathic pulmonary fi-
brosis; 
Whereas approximately 83,000 United States citizens have 
idiopathic pulmonary fibrosis, and 31,000 new cases are 
diagnosed each year; 
Whereas idiopathic pulmonary fibrosis is often misdiagnosed 
or underdiagnosed; 
Whereas the median survival rate for idiopathic pulmonary fi-
brosis patients is 2 to 3 years, and about two thirds of 
idiopathic pulmonary fibrosis patients die within 5 years; 
and 
Whereas a need has been identified to increase awareness and 
detection of this misdiagnosed and underdiagnosed dis-
order: Now, therefore, be it 
Resolved by the House of Representatives (the Senate 
concurring), That the Congress— 
(1) recognizes the need to pursue research into 
the causes, a treatment, and an eventual cure for id-
iopathic pulmonary fibrosis; 
(2) supports the work of advocates and organi-
zations in educating, supporting, and providing hope 
for individuals who suffer from idiopathic pulmonary
HCON 178 RFS 
fibrosis, including efforts to organize a National Idi-
opathic Pulmonary Fibrosis Awareness Week; 
(3) supports the designation of an appropriate 
week as National Idiopathic Pulmonary Fibrosis 
Awareness Week; 
(4) encourages the President to issue a procla-
mation designating a National Idiopathic Pulmonary 
Fibrosis Awareness Week; 
(5) congratulates advocates and organizations 
for their efforts to educate the public about idio-
pathic pulmonary fibrosis, while funding research to 
help find a cure for this disorder; and 
(6) supports the goals and ideals of National 
Idiopathic Pulmonary Fibrosis Awareness Week. 
Passed the House of Representatives September 29, 
2005. 
Attest: 
JEFF TRANDAHL, 
Clerk. 
By GERASIMOS C. VANS, 
Deputy Clerk.
graph (1) and submit to the Congress and the Sec-
retary of Health and Human Services a report that 
provides the findings of the review. 
(c) CONTINGENT REINSTATEMENT OF APPROVAL OF 
DRUG.—If the report under subsection (b) includes a de-
termination by the Comptroller General that the approval 
by the Food and Drug Administration of mifepristone was 
provided in accordance with section 505 of the Federal 
Food, Drug, and Cosmetic Act, the Secretary of Health 
and Human Services shall publish such statement in the 
Federal Register. Effective upon the expiration of 30 days 
after such publication, subsection (a) ceases to have any 
legal effect. 
Æ
‘‘§ 7329. Parkinson’s Disease research, education, and 
clinical centers 
‘‘(a) The Secretary, upon the recommendation of the 
Under Secretary for Health and pursuant to the provi-
sions of this section, shall designate six Department 
health-care facilities as the locations for centers of Parkin-
son’s Disease research, education, and clinical activities 
and (subject to the appropriation of sufficient funds for 
such purpose) shall establish and operate such centers at 
such locations in accordance with this section. 
‘‘(b) In designating locations for centers under sub-
section (a), the Secretary, upon the recommendation of the 
Under Secretary for Health, shall—
‘‘(1) designate each Department health-care fa-
cility that as of January 1, 2005, was operating a 
Parkinson’s Disease research, education, and clinical 
center unless (on the recommendation of the Under 
Secretary for Health) the Secretary determines that 
such facility does not meet the requirements of sub-
section (c) or has not demonstrated effectiveness in 
carrying out the established purposes of such center 
or the potential to carry out such purposes effec-
tively in the reasonably foreseeable future; and 
‘‘(2) assure appropriate geographic distribution 
of such facilities.
‘‘(c) The Secretary may not designate a health-care 
facility as a location for a center under subsection (a) un-
less the peer review panel established under subsection (d) 
has determined under that subsection that the proposal 
submitted by such facility as a location for a new center 
under subsection (a) is among those proposals which have 
met the highest competitive standards of scientific and 
clinical merit, and the Secretary (upon the recommenda-
tion of the Under Secretary for Health) determines that 
the facility has (or may reasonably be anticipated to de-
velop) each of the following: 
‘‘(1) An arrangement with an accredited med-
ical school which provides education and training in 
neurology and with which such facility is affiliated 
under which residents receive education and training 
in innovative diagnosis and treatment of chronic 
neurodegenerative diseases and movement disorders, 
including Parkinson’s disease. 
‘‘(2) The ability to attract the participation of 
scientists who are capable of ingenuity and creativity 
in health-care research efforts. 
‘‘(3) A policymaking advisory committee com-
posed of appropriate health-care and research rep-
resentatives of the facility and of the affiliated 
school or schools to advise the directors of such fa-
IV 
109TH CONGRESS 
1ST SESSION 
H. CON. RES. 179
Expressing the sense of the Congress regarding bone marrow failure diseases. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 16, 2005
Mr. BROWN of Ohio (for himself and Mr. BILIRAKIS) submitted the following 
concurrent resolution; which was referred to the Committee on Energy 
and Commerce 
CONCURRENT RESOLUTION 
Expressing the sense of the Congress regarding bone marrow 
failure diseases.
Whereas every year approximately 20,000 to 30,000 Ameri-
cans are diagnosed with aplastic anemia, myelodysplastic 
syndromes (MDS), or paroxysmal nocturnal hemo-
globinuria (PNH); 
Whereas bone marrow failure diseases can strike any person 
anywhere in the world, regardless of age, gender, race, or 
ethnicity; 
Whereas the highest incidence of these diseases occurs with 
people age 60 or older; 
Whereas the number of cases of these diseases will increase 
each year as the American population continues to age;
•HCON 179 IH 
Whereas bone marrow failure diseases occur when the bone 
marrow stops making enough healthy blood cells or pro-
duces poorly functioning blood cells; 
Whereas the causes of aplastic anemia, MDS, and PNH re-
main unknown, but are linked to toxins and viruses that 
commonly occur in our society and both prescription and 
over-the-counter medications; 
Whereas patients diagnosed with these diseases also suffer 
from anemia, bleeding, infections, and thrombosis; 
Whereas most treatments for bone marrow failure diseases 
are experimental, and there is no single cure for these 
diseases; 
Whereas the Aplastic Anemia & MDS International Founda-
tion is the Nation’s oldest and largest patient advocacy 
and support network for individuals suffering from bone 
marrow diseases; and 
Whereas the Congress as an institution and Members of Con-
gress as individuals are in unique positions to help raise 
public awareness about bone marrow failure diseases and 
to support the fight against these diseases: Now, there-
fore, be it
Resolved by the House of Representatives (the Senate 
concurring), That it is the sense of the Congress that—
(1) all Americans should gain a better under-
standing of bone marrow failure diseases and their 
symptoms; 
(2) all individuals diagnosed with bone marrow 
failure diseases and their families should have access 
to a variety of treatment and counseling options;
•HCON 179 IH 
(3) families coping with bone marrow failure 
diseases should be linked to support networks and 
counseling and information services provided by non-
profit organizations like the Aplastic Anemia & MDS 
International Foundation; and 
(4) the Federal Government should—
(A) endeavor to raise awareness about the 
importance of the early detection of, and proper 
treatment for, bone marrow failure diseases; 
(B) provide adequate funding for research 
into the causes of, and improved treatment for, 
bone marrow failure diseases; 
(C) engage in such public health initiatives 
as surveillance, education, and awareness of 
bone marrow failure diseases; and 
(D) continue to consider ways to improve 
access to, and the quality of, health care serv-
ices for detecting and treating bone marrow 
failure diseases.
Æ